Unmatched 1-Year Patency & 3-Year Freedom From TLR
The Supera™ Stent has been studied in over 8,000 patients worldwide in the SUPERB trial and over 70 publications. Notably, the studies, on Supera™ Peripheral Stent showed durable results with zero fractures at 1 year.1,23,*
*In studies where stent fracture were designated as an endpoint and reported.
SUPERB Trial
At 1 year the Supera™ Stent demonstrated primary patency of 91% when nominally* deployed. At 3 years, freedom from targeted lesion revascularization (TLR) was 94% when nominally* deployed.1
PATENCY (K-M) AT 1 YEAR
When nominally deployed*
FREEDOM FROM TLR AT 3 YEARS
When nominally deployed*
*Nominal deployment is defined as the stent length upon deployment being within +/- 10% of the labeled stent length. This data is from a non-powered post-hoc analysis. K-M=Kaplan Meier.
Consistent Patency Regardless of Lesion Length
With some peripheral stents, increasing lesion lengths can lead to decreasing patency rates.20 The Supera™ Stent stands apart for its consistently high patency rates in lesions spanning lengths from 5.3 cm up to 28.0 cm.†
† Published data was included if lesion length and patency were both available.
Note: Results from different clinical trials are not directly comparable. Information provided for educational purposes only.
Excellent Results from Simple to Complex Lesions
Whether treating simple (TASC A&B) or complex (TASC C&D) lesions, the Supera™ Stent is associated with impressive, consistent patency performance data at 1 year.1-4
| Simple | |||
|---|---|---|---|
 | Trial/Study | MUNICH REGISTRY2 | SUPERB1 |
| Lesion Length | 5.3 cm | 7.8 cm | |
| TASC A&B Lesions | 100% | 94% | |
| 1-Yr Patency | 86.7% | 90.5% | |
| Sites | Single Center | Multicenter (46 sites) | |
| # Patients | 70 | 264 | |
| Complex | |||
|---|---|---|---|
 | Trial/Study | ST. LOUIS4 | SUPERSUB3 |
| Lesion Length | 24 cm | 28 cm | |
| TASC C&D Lesions | 78% | 100% | |
| CTOs | Unknown | 100% | |
| 1-Yr Patency | 85.6% | 94.1% | |
| Sites | Single Center | Single Center | |
| # Patients | 48 | 34 | |
TASC: Trans-Atlantic Inter-Society Consensus
Endovascular Treatment Consideration for Common Femoral Artery
The Supera™ Stent has demonstrated positive long-term results out to 5 years.
| Common Femoral Artery* | |||
|---|---|---|---|
| Trial/Study | VMI-CFA21 | VMI-EXCEED22 | |
| Lesion Length | 4.42 cm | 3.86 cm | |
| Calcified Lesion % | 82% | 96.2% | |
| Patency | 2 year @ 92.8% | - | |
| Freedom from TLR | 2 year @ 97.8% | 5 year @ 93.3% | |
| # Patients | 100 | 156 | |
*Check the regulatory status of the device(s) in your region prior to use.
REFERENCES
- Garcia L. et al., Catheterization and Cardiovascular Interventions 2017 Jun 1;89(7):1259-1267.
- Treitl, K.M., et al. European Radiology.2017; 10.1007.
- Palena L.M. et al. Catheterization and Cardiovascular Intervention.2016.
- Brescia AA. et al., J Vasc Surg. 2015 Jun;61(6):1472-8
- George JC. et al., J Vasc Interv Radiol. 2014 Jun;25(6):954-61.
- Montero-Baker M. et al., J Vasc Surg. 2016 Oct;64(4):1002-8.
- Scheinert D. et al., J Endovasc Ther. 2011 Dec;18(6):745-52.
- Werner M. et al., EuroIntervention. 2014 Nov;10(7):861-8.
- San Norberto EM. et al., Ann Vasc Surg. 2017 May;41:186-195.
- Chan YC. et al., J Vasc Surg. 2015 Nov;62(5):1201-9.
- Dumantepe M. Vasc Endovascular Surg. 2017 Jul;51(5):240-246.
- Goltz JP. et al., J Endovasc Ther. 2012 Jun;19(3):450-6.
- León LR Jr. et al., J Vasc Surg. 2013 Apr;57(4):1014-22.
- Myint M. et al., J Endovasc Ther. 2016 Jun;23(3):433-41.
- Palena LM. et al., J Endovasc Ther. 2018 Oct;25(5):588-591.
- Scheinert D. et al., JACC Cardiovasc Interv. 2013 Jan;6(1):65-71.
- Steiner S. et al., J Endovasc Ther. 2016 Apr;23(2):347-55.
- Teymen B. et al., Vascular. 2018 Feb;26(1):54-61.
- Bhatt H. et al., Cardiovasc Revasc Med. 2018 Jul;19(5 Pt A):512-515.
- Shroë H. Superficial femoral artery PTA or stenting? 5-Year results. CIRSE 2011; Munich, Germany.
- K. Deloose, VIVA 2019.
- L. Maene, LINC 2026.
- Data on file at Abbott.
MAT-2635220 v3.0